Neo-Concept International Group Holdings Limited (NCI) Stock Competitors & Peer Comparison
See (NCI) competitors and their performances in Stock Market.
Peer Comparison Table: Apparel - Manufacturers Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NCI | $11.32 | -0.26% | 5.8M | 141.50 | $0.08 | N/A |
| RL | $411.16 | +0.26% | 25.1B | 24.80 | $16.58 | +0.90% |
| LEVI | $24.54 | +2.29% | 9.7B | 17.67 | $1.39 | +2.28% |
| GIL | $52.82 | -1.23% | 8.1B | 15.74 | $3.36 | +1.80% |
| VFC | $17.37 | +2.42% | 6.8B | 31.01 | $0.56 | +2.09% |
| KTB | $83.29 | +4.24% | 4.6B | 14.04 | $5.93 | +2.55% |
| ZGN | $13.15 | +1.94% | 3.5B | 27.28 | $0.48 | +1.09% |
| PVH | $74.38 | +3.29% | 3.4B | 6.65 | $11.18 | +0.20% |
| COLM | $64.51 | +1.02% | 3.3B | 17.92 | $3.60 | +1.87% |
| UAA | $6.30 | +3.62% | 2.7B | 52.38 | $0.12 | N/A |
Stock Comparison
NCI vs RL Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, RL has a market cap of 25.1B. Regarding current trading prices, NCI is priced at $11.32, while RL trades at $411.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas RL's P/E ratio is 24.80. In terms of profitability, NCI's ROE is +0.01%, compared to RL's ROE of +0.35%. Regarding short-term risk, NCI is more volatile compared to RL. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check RL's competition here
NCI vs LEVI Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, LEVI has a market cap of 9.7B. Regarding current trading prices, NCI is priced at $11.32, while LEVI trades at $24.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas LEVI's P/E ratio is 17.67. In terms of profitability, NCI's ROE is +0.01%, compared to LEVI's ROE of +0.28%. Regarding short-term risk, NCI is more volatile compared to LEVI. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check LEVI's competition here
NCI vs GIL Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, GIL has a market cap of 8.1B. Regarding current trading prices, NCI is priced at $11.32, while GIL trades at $52.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas GIL's P/E ratio is 15.74. In terms of profitability, NCI's ROE is +0.01%, compared to GIL's ROE of +0.10%. Regarding short-term risk, NCI is more volatile compared to GIL. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check GIL's competition here
NCI vs VFC Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, VFC has a market cap of 6.8B. Regarding current trading prices, NCI is priced at $11.32, while VFC trades at $17.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas VFC's P/E ratio is 31.01. In terms of profitability, NCI's ROE is +0.01%, compared to VFC's ROE of +0.16%. Regarding short-term risk, NCI is more volatile compared to VFC. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check VFC's competition here
NCI vs KTB Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, KTB has a market cap of 4.6B. Regarding current trading prices, NCI is priced at $11.32, while KTB trades at $83.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas KTB's P/E ratio is 14.04. In terms of profitability, NCI's ROE is +0.01%, compared to KTB's ROE of +0.50%. Regarding short-term risk, NCI is less volatile compared to KTB. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check KTB's competition here
NCI vs ZGN Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, ZGN has a market cap of 3.5B. Regarding current trading prices, NCI is priced at $11.32, while ZGN trades at $13.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas ZGN's P/E ratio is 27.28. In terms of profitability, NCI's ROE is +0.01%, compared to ZGN's ROE of +0.10%. Regarding short-term risk, NCI is more volatile compared to ZGN. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check ZGN's competition here
NCI vs PVH Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, PVH has a market cap of 3.4B. Regarding current trading prices, NCI is priced at $11.32, while PVH trades at $74.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas PVH's P/E ratio is 6.65. In terms of profitability, NCI's ROE is +0.01%, compared to PVH's ROE of +0.03%. Regarding short-term risk, NCI is more volatile compared to PVH. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check PVH's competition here
NCI vs COLM Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, COLM has a market cap of 3.3B. Regarding current trading prices, NCI is priced at $11.32, while COLM trades at $64.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas COLM's P/E ratio is 17.92. In terms of profitability, NCI's ROE is +0.01%, compared to COLM's ROE of +0.10%. Regarding short-term risk, NCI is more volatile compared to COLM. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check COLM's competition here
NCI vs UAA Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, UAA has a market cap of 2.7B. Regarding current trading prices, NCI is priced at $11.32, while UAA trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas UAA's P/E ratio is 52.38. In terms of profitability, NCI's ROE is +0.01%, compared to UAA's ROE of -0.30%. Regarding short-term risk, NCI is more volatile compared to UAA. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check UAA's competition here
NCI vs UA Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, UA has a market cap of 2.6B. Regarding current trading prices, NCI is priced at $11.32, while UA trades at $6.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas UA's P/E ratio is 50.42. In terms of profitability, NCI's ROE is +0.01%, compared to UA's ROE of -0.30%. Regarding short-term risk, NCI is less volatile compared to UA. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check UA's competition here
NCI vs HBI Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, HBI has a market cap of 2.3B. Regarding current trading prices, NCI is priced at $11.32, while HBI trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas HBI's P/E ratio is 5.53. In terms of profitability, NCI's ROE is +0.01%, compared to HBI's ROE of +1.91%. Regarding short-term risk, NCI is more volatile compared to HBI. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check HBI's competition here
NCI vs AIN Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, AIN has a market cap of 2.2B. Regarding current trading prices, NCI is priced at $11.32, while AIN trades at $76.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas AIN's P/E ratio is 36.13. In terms of profitability, NCI's ROE is +0.01%, compared to AIN's ROE of -0.08%. Regarding short-term risk, NCI is more volatile compared to AIN. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check AIN's competition here
NCI vs FIGS Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, FIGS has a market cap of 1.9B. Regarding current trading prices, NCI is priced at $11.32, while FIGS trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas FIGS's P/E ratio is 52.73. In terms of profitability, NCI's ROE is +0.01%, compared to FIGS's ROE of +0.10%. Regarding short-term risk, NCI is more volatile compared to FIGS. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check FIGS's competition here
NCI vs GIII Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, GIII has a market cap of 1.4B. Regarding current trading prices, NCI is priced at $11.32, while GIII trades at $34.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas GIII's P/E ratio is 15.21. In terms of profitability, NCI's ROE is +0.01%, compared to GIII's ROE of +0.07%. Regarding short-term risk, NCI is more volatile compared to GIII. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check GIII's competition here
NCI vs GOOS Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, GOOS has a market cap of 938.5M. Regarding current trading prices, NCI is priced at $11.32, while GOOS trades at $9.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas GOOS's P/E ratio is 17.91. In terms of profitability, NCI's ROE is +0.01%, compared to GOOS's ROE of +0.04%. Regarding short-term risk, NCI is more volatile compared to GOOS. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check GOOS's competition here
NCI vs OXM Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, OXM has a market cap of 535.3M. Regarding current trading prices, NCI is priced at $11.32, while OXM trades at $35.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas OXM's P/E ratio is 21.86. In terms of profitability, NCI's ROE is +0.01%, compared to OXM's ROE of -0.07%. Regarding short-term risk, NCI is more volatile compared to OXM. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check OXM's competition here
NCI vs MAGN Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, MAGN has a market cap of 447M. Regarding current trading prices, NCI is priced at $11.32, while MAGN trades at $12.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas MAGN's P/E ratio is -6.22. In terms of profitability, NCI's ROE is +0.01%, compared to MAGN's ROE of -0.10%. Regarding short-term risk, NCI is more volatile compared to MAGN. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check MAGN's competition here
NCI vs SGC Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, SGC has a market cap of 199.3M. Regarding current trading prices, NCI is priced at $11.32, while SGC trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas SGC's P/E ratio is 22.37. In terms of profitability, NCI's ROE is +0.01%, compared to SGC's ROE of +0.04%. Regarding short-term risk, NCI is less volatile compared to SGC. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check SGC's competition here
NCI vs VNCE Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, VNCE has a market cap of 99.7M. Regarding current trading prices, NCI is priced at $11.32, while VNCE trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas VNCE's P/E ratio is 12.72. In terms of profitability, NCI's ROE is +0.01%, compared to VNCE's ROE of +0.18%. Regarding short-term risk, NCI is less volatile compared to VNCE. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check VNCE's competition here
NCI vs FFFZ Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, FFFZ has a market cap of 68.8M. Regarding current trading prices, NCI is priced at $11.32, while FFFZ trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas FFFZ's P/E ratio is N/A. In terms of profitability, NCI's ROE is +0.01%, compared to FFFZ's ROE of N/A. Regarding short-term risk, NCI is more volatile compared to FFFZ. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check FFFZ's competition here
NCI vs JRSH Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, JRSH has a market cap of 57.9M. Regarding current trading prices, NCI is priced at $11.32, while JRSH trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas JRSH's P/E ratio is 16.29. In terms of profitability, NCI's ROE is +0.01%, compared to JRSH's ROE of +0.06%. Regarding short-term risk, NCI is more volatile compared to JRSH. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check JRSH's competition here
NCI vs CULP Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, CULP has a market cap of 39M. Regarding current trading prices, NCI is priced at $11.32, while CULP trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas CULP's P/E ratio is -5.05. In terms of profitability, NCI's ROE is +0.01%, compared to CULP's ROE of -0.13%. Regarding short-term risk, NCI is more volatile compared to CULP. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check CULP's competition here
NCI vs JL Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, JL has a market cap of 20.2M. Regarding current trading prices, NCI is priced at $11.32, while JL trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas JL's P/E ratio is 7.90. In terms of profitability, NCI's ROE is +0.01%, compared to JL's ROE of +0.31%. Regarding short-term risk, NCI is less volatile compared to JL. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check JL's competition here
NCI vs LLL Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, LLL has a market cap of 10.8M. Regarding current trading prices, NCI is priced at $11.32, while LLL trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas LLL's P/E ratio is -0.10. In terms of profitability, NCI's ROE is +0.01%, compared to LLL's ROE of N/A. Regarding short-term risk, NCI is more volatile compared to LLL. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check LLL's competition here
NCI vs XELB Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, XELB has a market cap of 7.7M. Regarding current trading prices, NCI is priced at $11.32, while XELB trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas XELB's P/E ratio is -0.59. In terms of profitability, NCI's ROE is +0.01%, compared to XELB's ROE of -0.90%. Regarding short-term risk, NCI is less volatile compared to XELB. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check XELB's competition here
NCI vs PMNT Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, PMNT has a market cap of 6.2M. Regarding current trading prices, NCI is priced at $11.32, while PMNT trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas PMNT's P/E ratio is -0.27. In terms of profitability, NCI's ROE is +0.01%, compared to PMNT's ROE of -10.56%. Regarding short-term risk, NCI is less volatile compared to PMNT. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check PMNT's competition here
NCI vs JXJT Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, JXJT has a market cap of 4.9M. Regarding current trading prices, NCI is priced at $11.32, while JXJT trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas JXJT's P/E ratio is 1.47. In terms of profitability, NCI's ROE is +0.01%, compared to JXJT's ROE of +0.22%. Regarding short-term risk, NCI is more volatile compared to JXJT. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check JXJT's competition here
NCI vs DLA Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, DLA has a market cap of 4.1M. Regarding current trading prices, NCI is priced at $11.32, while DLA trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas DLA's P/E ratio is -0.06. In terms of profitability, NCI's ROE is +0.01%, compared to DLA's ROE of -0.20%. Regarding short-term risk, NCI is less volatile compared to DLA. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check DLA's competition here
NCI vs EVK Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, EVK has a market cap of 0. Regarding current trading prices, NCI is priced at $11.32, while EVK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas EVK's P/E ratio is N/A. In terms of profitability, NCI's ROE is +0.01%, compared to EVK's ROE of -0.00%. Regarding short-term risk, NCI is less volatile compared to EVK. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check EVK's competition here
NCI vs SQBG Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, SQBG has a market cap of 0. Regarding current trading prices, NCI is priced at $11.32, while SQBG trades at $6.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas SQBG's P/E ratio is N/A. In terms of profitability, NCI's ROE is +0.01%, compared to SQBG's ROE of -1.42%. Regarding short-term risk, NCI is less volatile compared to SQBG. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check SQBG's competition here
NCI vs KBSF Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, KBSF has a market cap of 0. Regarding current trading prices, NCI is priced at $11.32, while KBSF trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas KBSF's P/E ratio is -1.46. In terms of profitability, NCI's ROE is +0.01%, compared to KBSF's ROE of -0.10%. Regarding short-term risk, NCI is less volatile compared to KBSF. This indicates potentially lower risk in terms of short-term price fluctuations for NCI.Check KBSF's competition here
NCI vs PERY Comparison June 2026
NCI plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NCI stands at 5.8M. In comparison, PERY has a market cap of 0. Regarding current trading prices, NCI is priced at $11.32, while PERY trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NCI currently has a P/E ratio of 141.50, whereas PERY's P/E ratio is N/A. In terms of profitability, NCI's ROE is +0.01%, compared to PERY's ROE of +0.15%. Regarding short-term risk, NCI is more volatile compared to PERY. This indicates potentially higher risk in terms of short-term price fluctuations for NCI.Check PERY's competition here